Embed Size (px)
Citation preview
Medical Affairs PharmD Fellowship
2019 - 2021
At Alkermes plc, our employees consistently strive to provide physicians and patients with treatment options that address important unmet needs. Through our scientific expertise, proprietary technologies and global resources, we are uniquely positioned to continue building a portfolio of medicines for major clinical conditions with a focus on central nervous system (CNS) disorders.
Our success to date is evident from our diverse commercial product portfolio, including treatments in major diseases, such as schizophrenia, addiction, diabetes and multiple sclerosis. Beyond our commercial products, we have a promising pipeline of proprietary drug candidates, many in late-stage development. Both our commercialized products and rich pipeline demonstrate our leadership in drug development for CNS diseases, a therapeutic area where we have established expertise and a promise for delivering new treatments.
Our Proprietary Products
Our commercial product portfolio reflects our years of experience in developing innovative and patient-inspired solutions. These unique products address patient needs in major disease areas.
ARISTADA® (aripiprazole lauroxil)extended-release injectable suspension is indicated for the treatment of schizophrenia. It is the first long-acting atypical antipsychotic with once-monthly, six-week and once-every-two-months dosing options.
VIVITROL® (naltrexone for extended-release injectable suspension) is an extended-release injectable formulation of naltrexone. It is the first and only non-narcotic, non-addictive, once-monthly medication for both alcohol and opioid dependence. Designed for once-monthly dosing, VIVITROL eliminates the need for patients to make a daily decision about taking their medicine. Alkermes commercializes VIVITROL in the U.S. Janssen Pharmaceuticals is responsible for the commercialization of VIVITROL in Russia and the Commonwealth of Independent States.
Products Using Alkermes Technologies
We have granted licenses under our proprietary technologies to enable third parties to develop, commercialize and, in some cases, manufacture products for which we receive royalties and/or manufacturing revenues
AMPYRA® (dalfampridine) is a twice-daily, controlled-release tablet indicated as a treatment to improve walking in patients with multiple sclerosis. AMPYRA is approved in the U.S. where it is marketed by Acorda Therapeutics, Inc. Biogen Inc. holds the rights to develop and commercialize the medication in all markets outside the U.S., where it is sold under the trade name FAMPYRA®.
BYDUREON® (exenatide extended-release for injectablesuspension) is a once-weekly therapy for the treatment of type 2 diabetes. BYDUREON is marketed in the U.S. and EU by AstraZeneca.
INVEGA SUSTENNA® (paliperidone palmitate), a Janssen product, is a once-monthly injectable form of paliperidone (INVEGA®) indicated for the treatment of schizophrenia and schizoaffective disorder. INVEGA SUSTENNA is commercialized under the trade name XEPLION® in the EU.
INVEGA TRINZA® (paliperidone palmitate), a Janssen product, is a three-month injectable form of paliperidone (INVEGA®) indicated for the treatment of schizophrenia. INVEGA TRINZA is commercialized under the trade name TREVICTA® in the EU.
RISPERDAL CONSTA® (risperidone), a Janssen product, is a long-acting injectable form of Janssen’s schizophrenia drug risperidone (RISPERDAL®). It is administered once every two weeks for the management of schizophrenia and bipolar I disorder. RISPERDAL CONSTA is commercialized by Janssen in more than 90 countries.
Alkermes plc is a fully integrated, global bio-pharmaceutical company focused on developing innovative medicines that address the unmet needs and challenges of people living with serious, chronic diseases.
WEBSITEwww.alkermes.com
TICKER SYMBOLNASDAQ: ALKS
HEADQUARTERS Connaught House 1 Burlington Road Dublin 4, Ireland+353 1 772 8000
EMPLOYEES Approximately 1,900 WW
CONTACTSCorporate CommunicationsVoice: +1 781 609 6143
Blair JacksonSenior Vice President, Business DevelopmentVoice: +1 781 609 6594
DescriptionThis two-year Fellowship Program in collaboration with Northeastern University and Alkermes plc is designed
to offer Doctor of Pharmacy graduates an in-depth experience in a biopharmaceutical industry setting. Alkermes has a diversified portfolio of commercially available medications and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia, and depression.
Alkermes Medical Affairs strives to educate healthcare communities and decision makers on the value of our products through the generation and dissemination of scientifically rigorous, accurate, and unbiased clinical, economic, and health outcomes information, with the goal of advancing healthcare. We accomplish this by partnering with internal Alkermes colleagues to catalyze science and knowledge and by serving as a bridge between Alkermes and the healthcare community.
Areas of Focus
Scientific Communication & Publications
Medical Strategy
Field Medical
Thought Leader Engagement
Medical Training
Medical Information
Health Economics and Outcomes Research
Medical Grants
What you will Experience
Understand various roles, processes and industry standards involved in the creation and dissemination ofmedical information in the pharmaceutical industry setting
Strategically plan, develop, and train on standard response letters
Contribute to the review of internal promotional and medical materials
Work closely with Medical Affairs team to develop training and scientific education for internal and external
stakeholders
Collaborate with cross-functional teams (regulatory, marketing, sales, legal, clinical development) to provide
Partner with Medical Directors to develop scientific materials that align with the scientific communication plan (e.g. manuscripts, abstracts, posters, slide decks)
]
How to Apply
and communicate the most up to date scientific information as a subject matter expert
For further questions, please email [email protected]
Medical Affairs PharmD Fellowship
]
Create, manage, and track strategic scientific communication plans in a cross-functional manner
]
]
]
]
]
]
]
]
]
]
]
]
]
Candidates who wish to apply must submit their curriculum vitae (CV), cover letter, and unofficial college transcript to [email protected]
AMPYRA® and FAMPYRA® are registered trademarks of Acorda Therapeutics, Inc. ARISTADA® is a trademark of Alkermes Pharma Ireland Limited. BYDUREON® is a registered trademark of Amylin Pharmaceuticals, LLC. RISPERDAL®, RISPERDAL CONSTA®, INVEGA®, INVEGA SUSTENNA®, XEPLION®, INVEGA TRINZA® and TREVICTA® are registered trademarks of Johnson & Johnson. VIVITROL® is a registered trademark of Alkermes, Inc.
CLINICAL DEVELOPMENT PROGRAMS
Preclinical Phase 1 Phase 2 Phase 3 FDA Review
Our rich pipeline of product candidates demonstrates our leadership in drug development for central nervous system (CNS) diseases, a therapeutic area where we have a proven track record of success. Backed by decades of experience, we are able to streamline clinical development time and substantially increase the probability of late-stage product success. The proof is in our substantial pipeline and its potential to have a unique and positive impact for patients.
CANDIDATE
ALKS 5461 (Major Depressive Disorder)
ALKS 3831 (Schizophrenia)
ALKS 8700 (Multiple Sclerosis)
ALKS 4230 (Immuno-oncology)
At Northeastern, we encourage our students to become engaged citizens of the world, confident, and resourceful people who realize that their knowledge and actions have positive effects on their own lives and those of others. Students ignite their passion for learning and are exposed to the endless possibilities around them through transformative experiential education. The School of Pharmacy provides a dynamic academic environment to guide and support Fellows toward successful careers in the biopharmaceutical industry and offers the opportunity to gain teaching and research experiences in an academic setting. The Northeastern faculty and Alkermes Fellowship preceptors mentor Fellows according to the Fellows’ scholarly and professional interests throughout the two-year program. As a visiting scholar at the School of Pharmacy, a Fellow will:
• Teach and coordinate courses and facilitate seminars and laboratories
• Create and publish scholarly research and review articles
• Present research at scientific and clinical meetings
• Collaborate with fellows and residents in the Boston area
